Evaluation of Three Continuation Therapies After ECT Concerning Efficacy and Cognition in Severly Depressed Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate three different continuation treatments after acute ECT concerning efficacy and impact on cognition in severly depressed patients.

Detailed Description
-----------------
BACKGROUND While electroconvulsive therapy (ECT) in major depression is effective, high relapse rates and cognitive effects limit its long-term use. Continuation treatment after ECT with combinations of C-ECT or psychotherapy and medication may decrease relapse rates and cognitive side effects while changing cognitive psychological variables like dysfunctional attitudes in the long-term. CENTRAL RESEARCH QUESTIONS Evaluation of the efficacy of three continuation treatments aimed at preventing relapses after acute ECT Examination of the cognitive side effects and the changes of cognitive psychological variables during acute and continuation treatment METHODS In a prospective, randomized, controlled, long-term study we assign 60 depressed ECT responder either to antidepressant treatment alone, or C-ECT plus medication, or cognitive behavioral group therapy plus medication. Depressive symptoms and cognition were assessed before, during, immediately after acute ECT and two, four, six, and 12 months during continuation therapy. HYPOTHESES It is hypothesized that the use of combination continuation therapies after effective ECT leads to lower HAMD scores and lower relapse rates than the standard treatment with antidepressants alone after 6 months. In addition, we assume that the CBT group will establish more functional macro-patterns than the somatic treatments in the long term and will have the lowest HAMD scores and relapse rates after 1 year. With regard to the cognitive side effects, the autobiographical memory is expected to be the only specific part of memory being affected negatively by ECT in the short and long term.

Official Title
-----------------
Phase 1 Study: Evaluation of Three Continuation Therapies After Acute Electroconvusive Therapy (ECT) Concerning Efficacy and Cognition in Severly Depressed Patients

Conditions
-----------------
Depression, Major Depression

Intervention / Treatment
-----------------
* Drug: TCAs, SSRIs, NARIs, SNRIs, Lithium
* Procedure: Electroconvulsive therapy
* Behavioral: Cognitive behavioral group therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Major depressive episode (unipolar) Response to acute ECT (at least 50% reduction in HAMD) Capacity to consent Sufficient comprehension of the German language Exclusion Criteria: Schizophrenia, schizoaffective disorder, or other psychosis Amnestic disorder, dementia, or delirium Pregnancy Epilepsy Current alcohol or substance abuse or dependence CNS disease or brain injury not associated with psychotropic drug exposure ECT in the past 3 months Acute suicidality Judiciary hospitalization

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>Continuation-Medication with Antidepressants (after WBS Guidelines) | Drug: TCAs, SSRIs, NARIs, SNRIs, Lithium<br>* Antidepressant, dosage, and duration are chosen due to the guidelines of the WFSBP (Bauer et al. 2002)<br>|
| Experimental: 2<br>Continuation-ECT with Antidepressants | Drug: TCAs, SSRIs, NARIs, SNRIs, Lithium<br>* Antidepressant, dosage, and duration are chosen due to the guidelines of the WFSBP (Bauer et al. 2002)<br>Procedure: Electroconvulsive therapy<br>* ECT treatment is administered three times per week on non-successive weekdays and according to existing standards. Treatment lasts for at least three weeks (nine ECT sessions). Psychopharmacological treatment is continued during ECT treatment. Patients receive ultrabrief pulse (0.3 ms), unilateral treatment at a frequency of 40-100 Hertz. Stimulation is applied to the non-dominant hemisphere, according to the d'Elia electrode positioning paradigm. All patients are initially treated with right unilateral stimulation and in case of non-response switched to bilateral treatment. Stimulus intensity is chosen according to individual seizure threshold and administered at 2.5 to 6-fold intensity. During the ECT session, patients are anesthetized, under the influence of a muscle relaxant, and monitored regarding their vital functions.<br>|
| Experimental: 3<br>Continuation-Psychotherapy (Cognitive Behavioral Group Psychotherapy including the Situational Analysis of CBASP) | Drug: TCAs, SSRIs, NARIs, SNRIs, Lithium<br>* Antidepressant, dosage, and duration are chosen due to the guidelines of the WFSBP (Bauer et al. 2002)<br>Behavioral: Cognitive behavioral group therapy<br>* The continuation-psychotherapy (continuation cognitive behavioral therapy, C-CBT) sample took part in a newly developed cognitive behavioral group therapy program called EffECTive. This therapy program was developed within the EffECT-project (Brakemeier et al. 2005), to fit the specific target group of patients finished with acute ECT-treatment. EffECTive is a group therapy that combines several aspects of existing cognitive-behavioral depression manuals with new elements (e.g., the situational analysis from CBASP, McCullough 2000), to fit the target group. Therapy sessions were held once a week and include approximately 15 sessions until follow-up.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Score on HAMD after 6 and 12 months |  | 6 and 12 months after enetering continuation phase | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Relapse rate after 6 and 12 months |  | 6 and 12 months after enetering continuation phase | 
| Response and remission rates after 6 and 12 months |  | 6 and 12 months after enetering continuation phase | 
| Scores on MADRS, BDI, and CGI after 6 and 12 months |  | 6 and 12 months after enetering continuation phase | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
therapy resistant depression, severe depression